Pallav D. Patel
Memorial Sloan-Kettering Cancer Center
New York, USA
Dr. Patel is a dynamic research professional at Memorial Sloan Kettering Cancer Center with an active interest in discovering novel anticancer agents. He is an author of over a dozen publications in peer reviewed journals -- Nature Chemical Biology and Cell-Chemistry & Biology amongst others. Dr. Patel’s work was featured on the Cell-Chemistry & Biology Journal cover (December 2013), highlighted in Cancer Discovery’s Research Watch (October 2013) and admired in Nature Science-Business eXchange (October 2013). He wrote grant proposals which resulted in NIH Exploratory and Developmental Research Grant Awards and has presented his findings at several National and International conferences. Dr. Patel’s research efforts resulted in to two PCT-Patent Applications and one US-Provisional Patent Application claiming composition of matter for anticancer treatment. He also serves as a Scientific Advisor at a patent law firm and is on the Editorial Board and Referee of 12 renowned scientific journals. Dr. Patel received his Ph.D, Masters and training in Pharmaceutical Sciences at Memorial Sloan Kettering Cancer Center, St. John’s University and Synta Pharmaceuticals (NASDAQ: SNTA).
Dr. Patel’s research interests are in the design, synthesis and development of novel anticancer drug molecules using a combined Medicinal Chemistry, Computational Chemistry and Biology approach. He is actively involved in various aspects of preclinical and clinical drug discovery process and has contributed significantly to the discovery and development of selective inhibitors of Grp94, one of the four Hsp90 family paralog, which is of high therapeutic relevance in HER2++ breast cancer. The compounds derived from his work are truly the first selective Grp94 inhibitors that would prevent any foreseen toxicity of non selective Hsp90 inhibitors -- currently in clinical trials.